Biopharmaceutical CDMO

Gene Engineering Driven
Innovative Biologics
R&D and Manufacturing

Specialized in GLP-1 analogs and recombinant insulin APIs, delivering end-to-end CDMO solutions from process development to commercial GMP manufacturing for global pharma.

Explore CDMO Services View Product Catalog
50+
Core Products
30+
Countries Served
99%+
Purity
GMP
Certified
Interactive rotating protein structure. Drag to rotate the model in 360 degrees and use the mouse wheel to zoom.
LIVE MOLECULAR VIEW Drag to rotate · Scroll to zoom
03
Tertiary structure Folded three-dimensional conformation
Amycretin / Zenagamtide·
Eloralintide·
NAD+ Lyophilized Powder·
Semaglutide·
Tirzepatide·
Liraglutide·
Dulaglutide·
Insulin Glargine·
Insulin Aspart·
Recombinant Human Insulin·
Cas9 Nuclease·
Cell Culture Factors·
cGMP Manufacturing·
Amycretin / Zenagamtide·
Eloralintide·
NAD+ Lyophilized Powder·
Semaglutide·
Tirzepatide·
Liraglutide·
Dulaglutide·
Insulin Glargine·
Insulin Aspart·
Recombinant Human Insulin·
Cas9 Nuclease·
Cell Culture Factors·
cGMP Manufacturing·
About Cellnuo

Nanjing Cellnuo
Biotechnology

Powered by gene engineering and recombinant protein technologies — dedicated to GLP-1 metabolic drug APIs and large-scale biologics manufacturing for the global pharmaceutical industry.

Cellnuo focuses on biopharmaceutical APIs for metabolic diseases, with flagship products covering GLP-1 analogs such as Semaglutide, Tirzepatide and Liraglutide, plus a full series of recombinant insulin APIs. The company maintains strategic collaborations with leading laboratories in Germany and the United States, providing high-purity, high-stability recombinant proteins, enzymes and cell culture factors with full technical support to global pharma, media manufacturers and research institutions.

GLP-1 Analogs Recombinant Insulin Cell Culture Factors CDMO Services Microbial Fermentation Protein Engineering CGT Products cGMP Compliant
Biomedical Research
cGMP Certified
ICH Q7 Standard
DMF Support
FDA · EMA · NMPA
Purity ≥ 99%
CoA / CoO Available
Global Partners
Germany · USA Labs
CDMO Services

End-to-End
Development & Manufacturing

From molecular design and process development to pilot scale-up and commercial GMP manufacturing, we deliver one-stop CDMO solutions spanning the entire biologics lifecycle.

01
Process Development
Process Development

Strain construction, media optimization, fermentation development, and downstream purification design — ensuring high purity and batch-to-batch consistency.

02
Pilot Scale-up
Pilot Scale-up

Systematic scale-up validation from lab to pilot to commercial — guaranteeing process robustness and seamless GMP transfer.

03
GMP Manufacturing
GMP Manufacturing

ICH Q7 compliant API production with electronic batch records, meeting strict quality requirements for IND and NDA filings.

04
Quality Control
Quality Control

Complete QC system covering physical-chemical analysis, bioactivity testing, impurity profiling and stability studies.

05
Regulatory Affairs
Regulatory Affairs

CTD-format DMF/ASMF authoring supporting FDA, EMA and NMPA submissions — accelerating global market entry.

06
Analytical Services
Analytical Services

Advanced instrumentation including HPLC, MS, CD spectroscopy supporting protein characterization, activity assays and impurity analysis.

Core Products

Product Portfolio

From next-generation peptides to recombinant insulin APIs, bioprocessing enzymes and regenerative biomaterials — engineered to power the next wave of biologics.

Innovative Peptides · NEW Innovative Peptides

Two investigational amylin programs, grouped together for research planning and evidence review.

Coming soon · Research program
GLP-1 + AMYLIN

Amycretin

Also known as Zenagamtide · NN9487 / NN9490

Amycretin is an investigational, unimolecular, long-acting peptide designed to activate both the GLP-1 and amylin receptors. These complementary pathways are being studied for their potential to support appetite regulation, satiety, glycaemic control and weight management within a single molecule.

Dual receptorGLP-1 + amylin agonist
Two formatsSubcutaneous and oral
Clinical statusPhase 3 obesity program initiated in 2026

Public clinical research has evaluated once-weekly subcutaneous and once-daily oral formulations in obesity and type 2 diabetes. Cellnuo lists this target for forward research planning only; availability, specifications and development timing remain subject to technical and legal review.

Investigational notice: Amycretin/zenagamtide is not an approved medicine. Cellnuo does not offer a finished dosage form. Any future material would be for lawful laboratory R&D use only, subject to applicable patent and regulatory restrictions.

NEW · Investigational amylin program
SELECTIVE AMYLIN

Eloralintide

LY3841136 · Selective amylin receptor agonist

Eloralintide is an investigational once-weekly peptide designed to selectively activate amylin receptors. The non-incretin mechanism is being studied for appetite and satiety regulation, lower calorie intake and weight management, both alone and as a complement to incretin therapy.

20.1%48-week Phase 2 mean weight change · 9 mg arm
Phase 3Five obesity studies initiated in 2026
2H 2026Tirzepatide combination Phase 2 data expected
What the human monotherapy data show

In a 48-week Phase 2 trial of 263 adults with obesity or overweight and no type 2 diabetes, mean weight reduction ranged from 9.5% to 20.1% across eloralintide arms versus 0.4% with placebo (efficacy estimand). The 3/6/9 mg gradual-escalation arm achieved 16.4%. The most common adverse events were mild-to-moderate gastrointestinal symptoms and fatigue, seen more often at higher doses.

Eloralintide + Tirzepatide · Current clinical status

Human clinical evidence: Phase 2 study NCT06603571 evaluates eloralintide and tirzepatide alone and in combination in 350 adults with obesity or overweight and type 2 diabetes. As of 16 July 2026, no human combination efficacy result has been publicly posted; Lilly expects data in the second half of 2026.

Preclinical signal · Not human efficacy

Animal study only: In diet-induced obese rats, four weeks of co-administration produced a 20% body-weight reduction, versus 10% with eloralintide and 9% with tirzepatide alone; adding eloralintide after two weeks of tirzepatide produced a 21% reduction. These results support clinical investigation but do not establish safety or efficacy in people.

Public evidence sources: Lilly Phase 2 NCT06603571 ADA 2026 preclinical

Investigational notice: Eloralintide is not an approved medicine. Clinical data are presented for scientific context only. Cellnuo does not provide a finished dosage form; any future material would be restricted to lawful laboratory R&D and applicable patent and regulatory requirements.

NEW
Fc-FGF21
Metabolic Regulator · MASH / Liver
Purity≥ 95.0%
SourceCHO Recombinant
UseMASH reversal · Insulin sensitivity
Metabolic & Obesity Metabolic & Obesity
NEW
Retatrutide
Triple GLP-1/GIP/Glucagon Agonist
Purity≥ 98.0%
SourceChemical / Recombinant
Specs500mg / 1g / Custom
Popular
Tirzepatide
Dual GLP-1/GIP Agonist
Purity≥ 98.5%
SourceChemical / Recombinant
Cert.GMP · CoA
Popular
Semaglutide
GLP-1 Receptor Agonist
Purity≥ 99.0%
SourceRecombinant E. coli
Cert.GMP · CoA · DMF
Mature
Liraglutide
GLP-1 Receptor Agonist
Purity≥ 99.0%
SourceRecombinant E. coli
Cert.GMP · DMF
Mature
Dulaglutide
Long-Acting GLP-1
Purity≥ 98.0%
SourceCHO Recombinant
Cert.Customized
Insulin & Analogues Insulin
NEW
Insulin Icodec
Once-Weekly Basal Insulin
Purity≥ 99.0%
SourceRecombinant E. coli
SpecsCustomized
NEW
Insulin Degludec
Ultra-Long-Acting Insulin
Purity≥ 99.0%
SourceRecombinant E. coli
SpecsCustomized
API
Insulin Glargine
Long-Acting Analog
Purity≥ 99.0%
SourceRecombinant E. coli
Cert.GMP · CoA
API
Insulin Aspart
Rapid-Acting Analog
Purity≥ 99.0%
SourceRecombinant E. coli
Cert.GMP
API
Insulin Lispro
Rapid-Acting Analog
Purity≥ 99.0%
SourceRecombinant E. coli
Cert.CoA · DMF
API
Human Insulin
Recombinant Human Insulin
Purity≥ 99.5%
SourceRecombinant E. coli
Cert.GMP · Ph.Eur
Bioprocessing Enzymes Enzymes
Enzyme
Kex2 Endoprotease
Site-Specific Cleavage Enzyme
Purity≥ 95%
SourceRecombinant Expression
UsePeptide / protein maturation
Enzyme
Carboxypeptidase B
Recombinant CPB · C-term Cleavage
Purity≥ 95%
SourceRecombinant Expression
UseInsulin / GLP-1 processing
Enzyme
Recombinant Trypsin
Animal-Free Trypsin
Purity≥ 97%
FeatureAnimal-free · Low endotoxin
UseCell culture · Protein
Growth Factors Growth Factors
Growth Factor
Recombinant EGF
Human Epidermal Growth Factor
Purity≥ 98%
SourceRecombinant E. coli
UseCell media · Skincare
Growth Factor
bFGF (FGF-2)
Basic Fibroblast Growth Factor
Purity≥ 95%
SourceRecombinant E. coli
UseStem cell · Tissue engineering
Growth Factor
IGF-1 LR3
Long R3 Insulin-Like Growth Factor
Purity≥ 97%
SourceRecombinant E. coli
UseCell media · CGT manufacturing
Aesthetic & Regenerative Aesthetic
NEW
NAD+ Lyophilized Powder
Nicotinamide Adenine Dinucleotide
FormLyophilized powder
GradeResearch grade
UseLaboratory R&D only
NEW
Type III Collagen
Recombinant Human Type III
Purity≥ 95%
SourceRecombinant Expression
UseSkin regeneration · Filler
NEW
Type XVII Collagen
Recombinant Human Type XVII
Purity≥ 95%
SourceRecombinant Expression
UseAnti-aging · Hair follicle
Biomaterial
Fibronectin
Recombinant Fibronectin
Purity≥ 95%
SourceRecombinant Expression
UseWound healing · Skincare
Biomaterial
PDRN
Polydeoxyribonucleotide
Purity≥ 98%
SourceSalmon DNA Extract
UseAesthetic · Tissue repair
Looking for another custom peptide?

Please contact our team separately to discuss sequence, purity, scale and research requirements.

Discuss your project
API
Insulin Glargine
Long-Acting Analog
Purity≥ 99.0%
SourceRecombinant E. coli
Specs1g / 5g / 10g
Cert.GMP · CoA
API
Insulin Aspart
Rapid-Acting Analog
Purity≥ 99.0%
SourceRecombinant E. coli
Specs1g / 5g / Custom
Cert.GMP
API
Insulin Lispro
Rapid-Acting Analog
Purity≥ 99.0%
SourceRecombinant E. coli
SpecsCustomized
Cert.CoA · DMF
API
Human Insulin
Recombinant Human Insulin
Purity≥ 99.5%
SourceRecombinant E. coli
Specs5g / 10g / 50g
Cert.GMP · Ph.Eur
CGT
Cas9 Nuclease
Gene-Editing Nuclease
Purity≥ 95%
SourceRecombinant E. coli
ActivityHigh cutting efficiency
UseGene editing · Research
Enzyme
Trypsin
Animal-Free Trypsin
Purity≥ 97%
FeatureAnimal-free · Low endotoxin
SpecsMultiple grades
UseCell culture · Protein
Growth Factor
EGF / FGF / IGF
Cell Growth Factors
Purity≥ 95%
SourceRecombinant E. coli
FeatureHigh bioactivity
UseCell media · Skincare
Enzyme
Nuclease
Nuclease Series
Purity≥ 95%
FeatureHigh specificity
SpecsMultiple grades
UseBiologics purification
Facilities

Modern GMP
Manufacturing Sites

Cellnuo operates state-of-the-art GMP API manufacturing facilities equipped with microbial fermenters, chromatography purification systems, and sterile injectable production lines — engineered precisely to deliver the highest quality standard for every batch. Click any video to view full screen.

Fermentation Systems
Chromatography Columns
Partner Facility
Downstream Purification
Pilot Plant
Schedule a Visit
FACILITY TOUR
Contact Us →
Our Process

One-Stop CDMO Workflow

From candidate molecule to commercial API — transparent, efficient collaboration that accelerates your global registration and launch.

01
Molecular Design
& Strain Construction

Gene synthesis, vector construction, host selection and high-expression clone screening

02
Process Development
& Optimization

Fermentation media optimization, induction studies, cell disruption process design

03
Pilot Scale-up
Validation

50L–1000L fermentation scale-up; batch consistency and process robustness validation

04
GMP Commercial
Manufacturing

ICH Q7 compliant, full electronic batch records, complete quality management system

05
Regulatory Filing
& Global Delivery

CTD-format DMF documents supporting FDA/EMA/NMPA registration

Contact & Locations

Let's Build
a Partnership

Our business team replies within one business day with product quotes, technical data sheets and CDMO collaboration proposals.

Lab & Office
Headquarters & Laboratory
First Floor, Building 5, Phase II, Zijin Fangshan, No. 199 Wenfang Road, Jiangning District, Nanjing, Jiangsu Province, China
Pilot Plant
Pilot Manufacturing Site
South side of 1st & 2nd Floors, Building A02, Phase III of Nanjing Biotech & Pharmaceutical Valley Accelerator, No. 142 Huakang Road, Jiangbei New Area, Nanjing
Official Inquiry
Business Email
sales@cellnuo.com
www.cellnuo.com
Mon–Fri 09:00–18:00 CST
Business Development
Liam White
Business Development Manager
+86 152 5513 5523
Huangxueyuan@cellnuo.com
Product Inquiry & Partnership
Fill in the details below and we will get back within one business day.